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Case report
Anakinra in the treatment of protracted
paradoxical inflammatory reactions in
HIV-associated tuberculosis in the United
Kingdom: a report of two cases
Alexander J Keeley1 , Vivak Parkash2, Anne Tunbridge2,
Julia Greig2, Paul Collini1 , William McKane3 and
Rachel S Tattersall4
Abstract
Paradoxical reactions, including immune reconstitution inflammatory syndrome (IRIS), are common in patients
co-infected with human immunodeficiency virus (HIV) and tuberculosis (TB). Paradoxical reactions may confer substan-
tial morbidity and mortality, especially in cases of central nervous system (CNS) TB, or through protracted usage of
corticosteroids. No high-quality evidence is available to guide management in this scenario. Interleukin-1-mediated
inflammation has been implicated in the pathophysiology of TB–IRIS. We describe two cases where anakinra (human
recombinant interleukin-1 receptor antagonist) was used as steroid-sparing therapy for life-threatening protracted
paradoxical inflammation in HIV-associated TB. In the first case of disseminated TB with lymphadenitis, protracted
TB–IRIS led to amyloid A amyloidosis and nephrotic syndrome. In the second case of disseminated TB with cerebral
tuberculomata, paradoxical inflammation caused unstable tuberculomata leading to profound neuro-disability. In both
cases, paradoxical inflammation persisted for over a year. Protracted high-dose corticosteroid use led to adverse events
yet failed to control inflammatory pathology. In both patients, anakinra successfully controlled paradoxical inflammation
and facilitated withdrawal of corticosteroid therapy. Following anakinra therapy, nephrotic syndrome and neuro-disability
resolved, respectively. Anakinra therapy for protracted paradoxical inflammation in HIV-associated TB may be a viable
therapeutic option and warrants further research.
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Introduction
Paradoxical inflammatory reactions in tuberculosis
(TB) are well described, characterised by disordered
inflammation to antigen of live or dead bacilli.
Patients (2–23%) with TB, develop worsening or new
inflammatory lesions despite anti-TB therapy.1 A par-
adoxical reaction in patients commencing antiretroviral
therapy (ART) for human immunodeficiency virus
(HIV) is termed TB-associated immune reconstitution
inflammatory syndrome (TB–IRIS), occurring with a
frequency of 5–57%.2
Modulating the immune response with corticoste-
roids improves survival in patients with
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TB-meningitis and reduces the frequency of TB–IRIS
in immunosuppressed patients with HIV and TB co-
infection.3,4 However, some patients experience para-
doxical reactions for months and even years, despite
appropriate TB therapy, and may require protracted
use of corticosteroids with significant treatment mor-
bidity. Successful use of several alternative agents
including thalidomide, interferon gamma, montelukast
and infliximab has been reported in case reports and
small case series.5
Interleukin-1 (IL-1) has been implicated as a key
mediator of the excessive immune responses in TB–
IRIS. IL-1 is a potent inflammatory mediator that
potentiates cell-mediated immune responses, upregu-
lates other inflammatory cytokines and promotes auto-
inflammation.6 IL-1 exists in alpha and beta forms,
although their activity is similar. In patients with
HIV and TB, those with IRIS, when compared to
non-IRIS controls, have an increased IL-1-mediated
cytokine profile that can be reduced by blocking IL-1
receptor signalling.7 Compared to non-IRIS patients
and HIV controls without TB, patients with TB-
meningitis and IRIS have higher levels of the IL-1b
activator, caspase 1, in their CSF and peripheral tran-
scriptomes associated with both IL-1- and neutrophil-
mediated inflammation.8 IL-1 receptor antagonist has a
physiological role in regulating IL-1-mediated
inflammation.
Anakinra is a recombinant IL-1 receptor antagonist
which is licenced for the treatment of rheumatoid
arthritis, the auto-inflammatory syndrome cryopyrin-
associated periodic syndrome, systemic juvenile idio-
pathic arthritis and its counterpart adult onset Still’s
disease. The licenced dose of anakinra is 100mg once
daily by subcutaneous (SC) injection. Clearance of ana-
kinra is directly related to renal function.9 Anakinra is
well tolerated although skin reactions at the site of
injection are not uncommon. There is increasing evi-
dence of safety even in severely immunocompromised
and/or septic patients.10–12 Anakinra has no significant
interactions with HIV or TB treatments. Furthermore,
from extensive data, TB reactivation attributed to ana-
kinra usage is extremely rare.13 We describe the
successful treatment with anakinra of two patients
with protracted paradoxical reactions in HIV-
associated TB.
Case 1
A 33-year-old Ethiopian female patient presented in
2009 with a two-week history of fever, myalgia, night
sweats and weight loss. On examination, the patient
had widespread lymphadenopathy. She was diagnosed
with HIV with a baseline CD4 cell count of
60 cells/mm3. Pus aspirated from a cervical lymph
node was acid-alcohol fast bacilli (AFB) smear positive
and grew fully-sensitive Mycobacterium tuberculosis on
culture. Cross-sectional imaging revealed cervical,
mediastinal and abdominal lymphadenopathy and
splenic microabscesses, consistent with disseminated
TB. She responded well to standard anti-TB therapy.
After two weeks of anti-TB therapy, she was com-
menced on ART with tenofovir, emtricitabine and efa-
virenz. Four weeks after ART initiation, the patient
developed pyrexia (39.2C) with abdominal pain,
nausea and vomiting. Following extensive investigation
to exclude alternative opportunistic infections, malig-
nancy and autoimmune disease, TB–IRIS was diag-
nosed with persistent large cervical and iliopsoas cold
abscesses requiring recurrent aspiration. Pus samples
were persistently positive for AFB and M. tuberculosis
by polymerase chain-reaction but mycobacterial cul-
tures were negative, consistent with protracted TB–
IRIS. She commenced 60mg prednisolone once daily.
However, over the next three years, she was unable to
tolerate a dose of less than 20 mg prednisolone daily,
due to relapsing fever, malaise, abdominal pain and
lymphadenopathy on each attempt to wean steroids.
She received two courses (12months and 9months) of
anti-TB therapy and developed multiple steroid-
associated adverse effects including diabetes, cataracts,
recurrent urinary tract infections and osteoporotic frac-
tures. Therapy with montelukast 10mg daily was used
to attempt suppression of IRIS, but with limited effect.
Two and a half years after her initial presentation, she
developed nephrotic syndrome: low serum albumin (21
g/L), significant proteinuria (10.5 g/day) and peripheral
oedema with preserved renal function. A diagnosis of
amyloid A (AA) amyloidosis was made on renal biopsy,
which showed mesangial and vascular amyloid deposi-
tion on sirius red staining, dichroic birefringence under
polarised light and 10 nm mesangial fibrils.
Immunofluorescence for amyloid P demonstrated glo-
merular staining and no evidence of Kappa/Lambda
clonality. She had a tenfold rise in serum amyloid A to
C-reactive protein (CRP) ratio, with a moderate renal
and splenic amyloid load on scinitigraphy with radio-
labelled serum amyloid P. Positron emission tomogra-
phy demonstrated highly metabolically active cervical,
mediastinal and abdominal lymph nodes. Histology
from a supraclavicular lymph node showed non-
specific chronic inflammatory changes only and no evi-
dence of malignancy or Castleman disease. Pus from
this lymph node remained AFB positive, with no myco-
bacterial growth on culture. She was referred to the
National Amyloid Centre UK, where she was assessed
as being in the worst prognostic octile for AA amyloid-
osis. Anakinra was proposed as a potential steroid
sparing agent to control her pro-inflammatory process,
due to its biological plausibility for both AA
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amyloidosis and IRIS and its rapid onset of action. In
conjunction with the local multidisciplinary team
including regional HIV, rheumatology and nephrology
specialists, she was commenced on anakinra in June
2013, at a dose of 100mg SC daily. Within three
months of starting anakinra, there was a discernible
improvement in her malaise, widespread painful lymph-
adenopathy and quality of life. Her inflammatory
markers and proteinuria normalised (Figure 1(a)).
Steroids were successfully weaned off over a year.
After six years of anakinra therapy (subsequently
reduced to 100mg on alternate days at five years), and
with stable calcified lymph node disease on cross-
sectional imaging, an attempt was made to stop ana-
kinra. However, 72 h after cessation, there was a rapid
recurrence of abdominal pain, fever and malaise with
associated rise in CRP (from 0.5 to 34mg/L) and eryth-
rocyte sedimentation rate (to 43mm/h). Anakinra was
re-initiated initially at 100mg daily for twoweeks,
achieving control of symptoms and normalisation of
inflammatory markers (Figure 2). She will remain on
100mg anakinra on alternate days lifelong.
Case 2
A 41-year-old male teacher from Zimbabwe presented
in 2016 with one month of fever, sweats and headache.
Medical history included pulmonary TB (2005) and
HIV with an undetectable viral load and a CD4 cell
count of 275 cells/mm3 on tenofovir, emtricitabine and
efavirenz ART. He was haemodynamically stable with
unremarkable examination and no neurological deficit.
Isoniazid monoresistant TB was diagnosed via culture
from bronchoalveolar lavage, with multiple miliary
nodules throughout both lung fields on cross-
sectional imaging. Magnetic resonance imaging
(MRI) of his brain revealed numerous foci of paren-
chymal high T2 signal in the right posterior and left
medulla, the pons bilaterally and both cerebellar hemi-
spheres, consistent with tuberculomata (Figure 1(b)).
Lumbar puncture was acellular with mild protein rise
of 0.61 g/L and normal glucose. He had been com-
menced empirically on rifampicin, isoniazid, ethambu-
tol, pyrazinamide, moxifloxacin, capreomycin and
cycloserine (given a history of TB treated in South
Africa), alongside dexamethasone 18mg (0.3mg/kg)
Figure 1. (a) Case 1 – Graph demonstrating progress of 24-h urine protein excretion, serum amyloid A (SAA) protein and serum
C-reactive protein (CRP) before and after initiation of anakinra therapy. Case 2 – Serial T2 weighted MRI brain scans at baseline (b),
18months (c) and three years (d) into illness, demonstrating progressive and unstable tuberculomata throughout both hemispheres
until 18months, with subsequent resolution following anakinra therapy.
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daily with a standard wean (reducing by 0.1mg/kg per
week).14 Two weeks into treatment, his headache wors-
ened and he developed new left-sided weakness and
paraesthesia. MRI brain confirmed an increase in
number and size of the lesions present requiring adjust-
ment of dexamethasone back to 18mg daily. Brain
biopsy demonstrated a necrotising granuloma; AFB
were visualised but there was no mycobacterial
growth, consistent with a paradoxical reaction.
Following TB culture and sensitivity results, his TB
regimen was rationalised to rifampicin, pyrazinamide,
moxifloxacin and ethambutol. After four months, he
was discharged with a dose of 8mg dexamethasone
daily, with a plan to wean by 1mg monthly. At
month 9 and at month 17, he required readmission
for ataxia, left hemiplegia and expressive dysphasia,
with significant functional and cognitive impairment.
He was unable to live independently. On both occa-
sions, MRI demonstrated worsening oedema and
unstable tuberculomata throughout both hemispheres,
brain stem and cerebellum (Figure 1(c)), prompting
recommencement of dexamethasone, 10mg daily.
Over this period, he developed Cushingoid appearance
and low mood. Thalidomide was trialled at month 17;
however, it was withdrawn one month later due to
peripheral neuropathy. Anakinra, 100mg SC, was
then initiated at 18months as a steroid sparing agent.
He remained on anakinra and weaned off corticoste-
roids over the next 18months (36months total dura-
tion) while he completed two years of anti-TB therapy
with rifampicin, pyrazinamide, moxifloxacin and
ethambutol. Since initiation of anakinra, there have
been no new tuberculomata and the existing lesions
have resolved (Figure 1(d)). Furthermore, his level of
function and cognition has improved significantly. He
lives independently and can mobilise with a stick with
only mild expressive language deficits (Figure 2).
Anakinra has been reduced to 100mg on alternate
days after two years.
Discussion
We have described two cases of paradoxical inflamma-
tion in TB that were insufficiently controlled by corti-
costeroid therapy and led to significant morbidity until
the introduction of the IL-1 receptor antagonist, ana-
kinra. Paradoxical reactions and IRIS are the cause of
substantial morbidity and occasional mortality in HIV/
TB co-infection, especially in TB of the CNS, if pro-
longed corticosteroid is required, or if uncontrolled
inflammation leads to AA amyloidosis.15 IL-1-
mediated inflammation has been implicated in the
pathogenesis of TB–IRIS in HIV in both CNS and
non-CNS disease.7,8 In the two cases presented here,
anakinra was used to achieve control of inflammation
and to reduce and stop steroids in patients at risk of
death or serious morbidity (in part due to high steroid
requirements) with protracted paradoxical reactions to
TB. We suggest that through down-regulating IL-1-
mediated inflammation, anakinra presents a viable
treatment option for refractory paradoxical inflamma-
tion in TB. Further research to evaluate the therapeutic
role of anakinra, particularly in less well-resourced
health systems with a high burden of HIV/TB
co-infection is required.
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Figure 2. Patient perspectives; each patient was asked to
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